Aflibercept in wet AMD beyond the first year of treatment: Recommendations by an expert roundtable panel

Eye (Basingstoke)

Volumn 29, Issue S1, 2015, Pages S1-S11

  McKibbin, M ^a   Devonport, H ^b   Gale, R ^c   Gavin, M ^d   Lotery, A ^e   Mahmood, S ^f,g   Patel, P J ^h   Ross, A ⁱ   Sivaprasad, S ^h   Talks, J ^j   Walters, G ^k  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b BRADFORD ROYAL INFIRMARY   (United Kingdom)

^c YORK HOSPITAL   (United Kingdom)

^d NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^e SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^f MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ BRISTOL EYE HOSPITAL   (United Kingdom)

^j ROYAL VICTORIA INFIRMARY   (United Kingdom)

^k HARROGATE DISTRICT HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; CENTRAL RETINAL THICKNESS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; UNITED KINGDOM; VISION; VISUAL ACUITY; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; INTRAVITREAL DRUG ADMINISTRATION; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; INTRAVITREAL INJECTIONS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84944456658     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.77     Document Type: Review

References (19)

1. American Academy of Ophthalmology. Age-related macular degeneration and other causes of choroidal neovascularization. In: Retina and Vitreous Basic and Clinic Science Course. American Academy of Ophthalmology: San Fransisco, 2013, pp 55-87.
2. Owen C, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 2012; 96(5): 752-756.
3. Fletcher EC, Chong N, Shetlar DJ. Retina. In: Riordan-Eva P, Whitcher JP (eds). General Ophthalmology. Mc-Graw Hill: New York, 2007, pp 186-188.
4. Lim JI, Tsong JW. Exudative (neovascular) age-related macular degeneration. In: Lim JI (ed). Age-related macular degeneration. Informa: Florida, 2007, pp 125-157.
5. Rudge JS, Ioffe E, Cao J, Papadopoulos N, Thurston G, Wiegand SJ et al. Clincal development of VEGF trap biology of VEGF and its receptors. In: Figg WD, Folkman J (eds). Angiogenesis. Springer: New York, 2008, pp 415-420.
6. European Medicines Compendium. EYLEA Summary of Product Characteristics. Accessed November 2014. Available from https://www.medicines.org.uk/emc/medicine/27224.
7. Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119(12): 2537-2548.
8. Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninetysix- week results of the VIEW studies. Ophthalmology 2014; 121(1): 193-201.
9. National Institute for Health and Care Excellence. Aflibercept solution for injection for treating wet age-related macular degeneration. Accessed November 2014. Available from http://www.nice.org.uk/guidance/ta155.
10. National Institute for Health and Care Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. Accessed November 2014. Available from http://www.nice.org.uk/guidance/ta155.
11. The Royal College of Ophthalmologists. Age-Related Macular Degeneration: Guidelines for Management 2013. Accesssed November 2014. Available from http://www.rcophth.ac.uk/page.asp?section=451.
12. Novartis Pharmaceuticals UK Ltd. Lucentis Summary of Product Characteristics. Accessed December 2014. Available from http://www.medicines.org.uk/EMC/medicine/19409/SPC/Lucentis+10+mg+ml+solution+for+injection/.
13. Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, Grunwald JE et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119(7): 1388-1398.
14. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382(9900): 1258-1267.
15. Gisbert Richard for the VIEW study group. Evaluation of subgroup receiving the minimum required injections in Year 2 of an integrated analysis of the VIEW studies. In: EURETINA 2014, 11-14 September 2014. London, UK.
16. Martin DF, Maguire MG, Ying G, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 2011; 364(20): 1897-1908.
17. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120(11): 2292-2299.
18. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group. Arch Ophthalmol 1993; 111(9): 1189-1199.
19. Tufail A. The neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections: Report 1: Visual acuity manuscript no. 2013-568. Ophthalmology 2014; 121: 1092-1101.